Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

H.C. Wainwright analyst Arthur He raised the firm’s price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating ...

Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.

The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...

Enphase Energy a company exhibitor seen at the Bepositive Energy ... More Transition Show. (Photo by Romain Doucelin/SOPA ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

Robinhood Markets Inc (NASDAQ:HOOD) stock is trending on Wednesday after hitting all-time highs this week. Here's a look at ...

US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on ...

Major indices closed higher on Tuesday despite Israeli claims that Iran had already breached a ceasefire agreement.

US Dollar South African Rand, Nasdaq 100, S&P 500, Alphabet Inc Class A. Read 's Market Analysis on Investing.com ZA.